32366-73-7Relevant articles and documents
Inhibition of bacterial growth and galactosyltransferase activity of WbwC by α, ω-bis(3-alkyl-1H-imidazolium)alkane salts: Effect of varying carbon content
Brockhausen, Inka,Kocev, Alexander,Kong, Xianqi,Melamed, Jacob,Szarek, Walter A.,Vlahakis, Jason Z.,Wang, Shuo,Xu, Yaozu
, (2020/04/21)
A series of compounds was designed and synthesized having two imidazolium rings separated by a polymethylene spacer and having alkyl substituents on each of the imidazolium rings. The compounds were assayed for their effects on the activity of galactosyltransferase WbwC, and also on the growth of Gram-negative and Gram-positive bacteria, as well as human cells. The inhibition observed on enzyme activities and cell growth was dependent on the total number of carbons in the spacer and the alkyl substituents on the imidazolium rings. These readily synthesized, achiral compounds have potential as antimicrobial and antiseptic agents.
Linker compound for imaging application
-
Paragraph 0077-0079, (2019/05/01)
The present invention relates to an imaging linker compound which can be applied to an imaging composition by being combined with a dye or the like. The imaging linker compound is represented by chemical formula 1a. In chemical formula 1a, R is succinimidyloxyl or ethenesulfonylC_(1-6)alkylaminyl, A is C_(1-3)alkyleneoxyC_(1-3)alkylene, and n is an integer of 1 to 100.COPYRIGHT KIPO 2019
BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME
-
Paragraph 00357-00361; 00380; 00381, (2015/06/11)
Described herein are compounds capable of modulating one or more biomolecules substantially simultaneously, e.g., modulating two or more binding domains (e.g., bromodomains) on a protein or on different proteins. For example, in one aspect, a bivalent compound or a pharmaceutically acceptable salt, stereoisomer, metabolite, or hydrate thereof is provided. In another aspect, a method of treating a disease associated with a protein having tandem bromodomains in a patient in need thereof is provided. The method comprises administering to the patient the bivalent compound as described.